RU2005117792A - Терапевтические агенты - Google Patents
Терапевтические агенты Download PDFInfo
- Publication number
- RU2005117792A RU2005117792A RU2005117792/04A RU2005117792A RU2005117792A RU 2005117792 A RU2005117792 A RU 2005117792A RU 2005117792/04 A RU2005117792/04 A RU 2005117792/04A RU 2005117792 A RU2005117792 A RU 2005117792A RU 2005117792 A RU2005117792 A RU 2005117792A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- carbamoyl
- carbamoylmethoxy
- dioxo
- methylthio
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 3
- 229940124597 therapeutic agent Drugs 0.000 title claims 2
- -1 carboxyl hydroxy group Chemical group 0.000 claims 28
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000006239 protecting group Chemical group 0.000 claims 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- LGSFSABIQCWSEV-FQEVSTJZSA-N (2s)-2-ethoxy-3-[4-[2-[ethyl-[[4-(trifluoromethoxy)phenyl]methyl]amino]-2-oxoethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)N(CC)CC1=CC=C(OC(F)(F)F)C=C1 LGSFSABIQCWSEV-FQEVSTJZSA-N 0.000 claims 2
- RQEWSKZIIGTCBH-FQEVSTJZSA-N (2s)-2-ethoxy-3-[4-[2-[ethyl-[[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)N(CC)CC1=CC=C(C(F)(F)F)C=C1 RQEWSKZIIGTCBH-FQEVSTJZSA-N 0.000 claims 2
- AAYNVHJZHNXYRQ-FQEVSTJZSA-N (2s)-3-[4-[2-[(4-chlorophenyl)methyl-ethylamino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)N(CC)CC1=CC=C(Cl)C=C1 AAYNVHJZHNXYRQ-FQEVSTJZSA-N 0.000 claims 2
- XACALORYRWKJSU-QFIPXVFZSA-N (2s)-3-[4-[2-[butyl-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C=1C=C(C[C@H](OCC)C(O)=O)C=CC=1OCC(=O)N(CCCC)CC1=CC=C(C(F)(F)F)C=C1F XACALORYRWKJSU-QFIPXVFZSA-N 0.000 claims 2
- YISNYCSHIRZSMM-QFIPXVFZSA-N (2s)-3-[4-[2-[butyl-[[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C=1C=C(C[C@H](OCC)C(O)=O)C=CC=1OCC(=O)N(CCCC)CC1=CC=C(C(F)(F)F)C=C1 YISNYCSHIRZSMM-QFIPXVFZSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- CWHZHSAJEOKUOJ-SFHVURJKSA-N (2s)-2-ethoxy-3-[4-[2-[[2-fluoro-4-(trifluoromethyl)phenyl]methylamino]-2-oxoethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)NCC1=CC=C(C(F)(F)F)C=C1F CWHZHSAJEOKUOJ-SFHVURJKSA-N 0.000 claims 1
- OZIFULIQIAYMBA-SFHVURJKSA-N (2s)-2-ethoxy-3-[4-[2-oxo-2-[[4-(trifluoromethoxy)phenyl]methylamino]ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)NCC1=CC=C(OC(F)(F)F)C=C1 OZIFULIQIAYMBA-SFHVURJKSA-N 0.000 claims 1
- XPCCFHSTPYREAN-SFHVURJKSA-N (2s)-2-ethoxy-3-[4-[2-oxo-2-[[4-(trifluoromethyl)phenyl]methylamino]ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)NCC1=CC=C(C(F)(F)F)C=C1 XPCCFHSTPYREAN-SFHVURJKSA-N 0.000 claims 1
- QVGLWHSPHJQMLW-SFHVURJKSA-N (2s)-3-[4-[2-[(4-chlorophenyl)methylamino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCC(=O)NCC1=CC=C(Cl)C=C1 QVGLWHSPHJQMLW-SFHVURJKSA-N 0.000 claims 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 claims 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 229940125922 IBAT inhibitor Drugs 0.000 claims 1
- 229940077672 Ileal bile acid transport inhibitor Drugs 0.000 claims 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 claims 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000012351 deprotecting agent Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 CCOC(Cc(cc1)ccc1OCC(O)=O)C(*)=O Chemical compound CCOC(Cc(cc1)ccc1OCC(O)=O)C(*)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0229931.1 | 2002-12-21 | ||
| GBGB0229931.1A GB0229931D0 (en) | 2002-12-21 | 2002-12-21 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005117792A true RU2005117792A (ru) | 2006-01-27 |
Family
ID=9950253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005117792/04A RU2005117792A (ru) | 2002-12-21 | 2003-12-19 | Терапевтические агенты |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7462644B2 (https=) |
| EP (1) | EP1572626A1 (https=) |
| JP (2) | JP3786945B2 (https=) |
| KR (1) | KR20050089065A (https=) |
| CN (1) | CN1308291C (https=) |
| AR (1) | AR042632A1 (https=) |
| AU (1) | AU2003290309B2 (https=) |
| BR (1) | BR0317458A (https=) |
| CA (1) | CA2508851A1 (https=) |
| CL (1) | CL2003002683A1 (https=) |
| CO (1) | CO5580820A2 (https=) |
| GB (1) | GB0229931D0 (https=) |
| IS (1) | IS7946A (https=) |
| MX (1) | MXPA05006812A (https=) |
| NO (1) | NO20052914L (https=) |
| PL (1) | PL377144A1 (https=) |
| RU (1) | RU2005117792A (https=) |
| TW (1) | TW200508180A (https=) |
| UA (1) | UA80729C2 (https=) |
| WO (1) | WO2004056748A1 (https=) |
| ZA (1) | ZA200504730B (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| DE60326436D1 (en) | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
| OA12793A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase. |
| MXPA04008796A (es) | 2002-03-13 | 2004-11-26 | Janssen Pharmaceutica Nv | Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona. |
| KR20040093692A (ko) | 2002-03-13 | 2004-11-08 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의 피페라지닐-,피페리디닐- 및 모르폴리닐-유도체 |
| PL375074A1 (en) | 2002-06-20 | 2005-11-14 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US8193205B2 (en) | 2004-07-28 | 2012-06-05 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| US8003617B2 (en) * | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| AU2006248938B2 (en) | 2005-05-18 | 2011-09-29 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| CA2610354C (en) | 2005-05-31 | 2011-03-29 | Pfizer Inc. | Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists |
| WO2007004957A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | Novel crystalline form |
| AR055073A1 (es) * | 2005-07-11 | 2007-08-01 | Astrazeneca Ab | Agentes terapeuticos |
| AU2007206942B2 (en) | 2006-01-19 | 2012-08-23 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| US7834011B2 (en) | 2006-01-19 | 2010-11-16 | Janssen Pharmaceutica N.V. | Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase |
| SI1981874T1 (sl) | 2006-01-19 | 2009-10-31 | Janssen Pharmaceutica Nv | Aminofenilni derivati kot novi inhibitorji histon deacetilaze |
| WO2007082880A1 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| AU2007206944B2 (en) | 2006-01-19 | 2012-08-23 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| JP5137849B2 (ja) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体 |
| PL2032134T3 (pl) | 2006-05-09 | 2015-11-30 | Genzyme Corp | Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów |
| EP2594562B1 (en) | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| ES2660690T3 (es) | 2007-10-05 | 2018-03-23 | Genzyme Corporation | Método para tratar poliquistosis renales con derivados de ceramida |
| CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP3078373A1 (en) | 2008-10-03 | 2016-10-12 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitor |
| CA2744817C (en) * | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| PH12013500547A1 (en) | 2010-09-22 | 2013-06-10 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| PL3400944T3 (pl) | 2010-11-04 | 2020-11-16 | Albireo Ab | Inhibitory ibat w leczeniu chorób wątroby |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES2942443T3 (es) | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| HUE060905T2 (hu) | 2019-02-06 | 2023-04-28 | Albireo Ab | Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| ES2973549T3 (es) | 2019-12-04 | 2024-06-20 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE266121C (https=) | ||||
| BE489216A (https=) | 1948-06-05 | 1900-01-01 | ||
| US2928840A (en) | 1958-11-26 | 1960-03-15 | Us Vitamin Pharm Corp | 3-(o-substituted phenyl) oxazolidinediones and process therefor |
| GB1081471A (en) | 1963-09-13 | 1967-08-31 | Stauffer Chemical Co | Glycol amide derivatives and use thereof in controlling weed growth |
| US3244398A (en) | 1963-10-28 | 1966-04-05 | Scaramucci Domer | Composite seat ball valve |
| AT307640B (de) | 1970-06-18 | 1973-05-25 | Richter Gedeon Vegyeszet | Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen |
| BE792364A (fr) | 1971-12-06 | 1973-06-06 | Basf Ag | Derives de substitution du sulfonylglycolanilide |
| DE2349256C2 (de) | 1973-10-01 | 1985-08-01 | Basf Ag, 6700 Ludwigshafen | 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide |
| DE2828222A1 (de) | 1978-06-28 | 1980-01-10 | Bayer Ag | Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide |
| US4735959A (en) | 1981-01-10 | 1988-04-05 | Dr. Karl Thomae Gmbh | Carboxylic acid amides and pharmaceutical compositions containing them |
| US5312924A (en) | 1983-12-30 | 1994-05-17 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US5216167A (en) | 1983-12-30 | 1993-06-01 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| US5210208A (en) | 1990-09-24 | 1993-05-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity |
| US5958792A (en) | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
| CA2298601A1 (en) | 1997-08-28 | 1999-03-11 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
| US6410585B1 (en) | 1997-08-28 | 2002-06-25 | Scott D. Larsen | Inhibitors of protein tyrosine phosphatase |
| IL135177A0 (en) * | 1997-10-02 | 2001-05-20 | Sankyo Co | Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same |
| AU1457299A (en) | 1997-11-12 | 1999-05-31 | Ariad Pharmaceuticals, Inc. | Novel signal transduction inhibitors, compositions containing them |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| PL351898A1 (en) | 1999-04-06 | 2003-06-30 | Sankyo Co | O-substituted derivatives of carboxylic acids |
| JP2000351777A (ja) * | 1999-04-08 | 2000-12-19 | Sankyo Co Ltd | 置換縮合イミダゾール誘導体 |
| WO2000061582A1 (en) | 1999-04-08 | 2000-10-19 | Sankyo Company, Limited | Substituted fused imidazole derivatives |
| WO2000061584A1 (en) | 1999-04-14 | 2000-10-19 | The University Of British Columbia | IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| NZ515086A (en) | 1999-04-28 | 2003-10-31 | Aventis Pharma Gmbh | Di-aryl acid derivatives as PPAR receptor ligands |
| JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| JP2001261612A (ja) | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| WO2002044127A1 (fr) | 2000-11-29 | 2002-06-06 | Kyorin Pharmaceutical Co., Ltd. | Dérivés d'acide carboxylique substitué |
| AU2002222550A1 (en) | 2000-11-29 | 2002-06-11 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
| EP1360172A1 (en) | 2001-02-15 | 2003-11-12 | Pfizer Products Inc. | Ppar agonists |
| WO2002083616A1 (en) | 2001-04-10 | 2002-10-24 | Sankyo Company, Limited | α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| EP1517882A1 (en) * | 2002-06-19 | 2005-03-30 | Eli Lilly And Company | Amide linker peroxisome proliferator activated receptor modulators |
| GB0314134D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314136D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2002
- 2002-12-21 GB GBGB0229931.1A patent/GB0229931D0/en not_active Ceased
-
2003
- 2003-12-10 TW TW092134839A patent/TW200508180A/zh unknown
- 2003-12-18 CL CL200302683A patent/CL2003002683A1/es unknown
- 2003-12-19 JP JP2004561668A patent/JP3786945B2/ja not_active Expired - Fee Related
- 2003-12-19 AU AU2003290309A patent/AU2003290309B2/en not_active Ceased
- 2003-12-19 US US10/499,893 patent/US7462644B2/en not_active Expired - Fee Related
- 2003-12-19 MX MXPA05006812A patent/MXPA05006812A/es unknown
- 2003-12-19 UA UAA200505596A patent/UA80729C2/uk unknown
- 2003-12-19 EP EP03782668A patent/EP1572626A1/en not_active Withdrawn
- 2003-12-19 WO PCT/GB2003/005602 patent/WO2004056748A1/en not_active Ceased
- 2003-12-19 AR ARP030104752A patent/AR042632A1/es unknown
- 2003-12-19 CA CA002508851A patent/CA2508851A1/en not_active Abandoned
- 2003-12-19 CN CNB2003801098952A patent/CN1308291C/zh not_active Expired - Fee Related
- 2003-12-19 PL PL377144A patent/PL377144A1/pl not_active Application Discontinuation
- 2003-12-19 BR BR0317458-1A patent/BR0317458A/pt not_active IP Right Cessation
- 2003-12-19 KR KR1020057011714A patent/KR20050089065A/ko not_active Withdrawn
- 2003-12-19 RU RU2005117792/04A patent/RU2005117792A/ru not_active Application Discontinuation
-
2005
- 2005-06-15 NO NO20052914A patent/NO20052914L/no not_active Application Discontinuation
- 2005-06-22 ZA ZA200504730A patent/ZA200504730B/en unknown
- 2005-07-19 IS IS7946A patent/IS7946A/is unknown
- 2005-07-19 CO CO05071340A patent/CO5580820A2/es not_active Application Discontinuation
- 2005-09-01 JP JP2005253346A patent/JP2006045240A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR042632A1 (es) | 2005-06-29 |
| ZA200504730B (en) | 2006-09-27 |
| EP1572626A1 (en) | 2005-09-14 |
| TW200508180A (en) | 2005-03-01 |
| KR20050089065A (ko) | 2005-09-07 |
| PL377144A1 (pl) | 2006-01-23 |
| MXPA05006812A (es) | 2005-09-08 |
| WO2004056748A1 (en) | 2004-07-08 |
| GB0229931D0 (en) | 2003-01-29 |
| JP2006511572A (ja) | 2006-04-06 |
| UA80729C2 (en) | 2007-10-25 |
| CL2003002683A1 (es) | 2005-04-08 |
| US20050131068A1 (en) | 2005-06-16 |
| AU2003290309B2 (en) | 2007-01-18 |
| NO20052914L (no) | 2005-07-19 |
| CN1753862A (zh) | 2006-03-29 |
| JP2006045240A (ja) | 2006-02-16 |
| BR0317458A (pt) | 2005-11-16 |
| NO20052914D0 (no) | 2005-06-15 |
| IS7946A (is) | 2005-07-19 |
| JP3786945B2 (ja) | 2006-06-21 |
| CA2508851A1 (en) | 2004-07-08 |
| US7462644B2 (en) | 2008-12-09 |
| CO5580820A2 (es) | 2005-11-30 |
| CN1308291C (zh) | 2007-04-04 |
| AU2003290309A1 (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005117792A (ru) | Терапевтические агенты | |
| RU2004116917A (ru) | Производные замещенной фенлпропионовой кислоты как агонисты активируемого пролифератором пероксисом альфа рецептора человека | |
| JP2006045240A5 (https=) | ||
| RU2004138083A (ru) | Комбинация ингибитора транспорта желчных кислот в подвздошной кишке (ibat) и соли металла для лечения диареи | |
| RU2008129204A (ru) | Применение ингибитора ibat для лечения или профилактики запора | |
| RU2333205C2 (ru) | Производные бензотиадиазепина, способ их получения и их применение, фармацевтическая композиция, обладающая ингибирующей активностью в отношении переноса желчных кислот в подвздошной кишке | |
| RU2005100836A (ru) | Производные пептидов, содержащие тиазепиновую группу, для лечения гиперлипемических состояний | |
| US20070244198A1 (en) | Carboxylic Derivatives | |
| CA2431461A1 (en) | 1,5 benzothiazepines and their use as antihyperlipidemics | |
| JP2004516285A5 (https=) | ||
| US20050267149A1 (en) | Benzoic acid derivatives as modulators of ppar alpha and gamma | |
| RU2004117776A (ru) | Производные 3-фенил-2-арилалкилтиопропионовой кислоты в качестве селективных антагонистов ppar-альфа | |
| JP2005511785A5 (https=) | ||
| JP3927594B2 (ja) | （−）−２−｛［２−（４−ヒドロキシフェニル）エチル］チオ｝−３−［４−（２−｛４−［（メチルスルホニル）オキシ］フェノキシ｝エチル）フェニル］プロパン酸のアミン塩および医学におけるそれらの使用 | |
| DE60319084T2 (de) | Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz | |
| ES2299703T3 (es) | Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina. | |
| KR20060026427A (ko) | (-)-2-([2-(4-히드록시페닐)에틸]티오)-3-[4-(2-(4-[(메틸설포닐)옥시]페녹시)에틸)페닐]-프로판산 칼륨염 또는나트륨염 및 이들의 약제로서의 용도 | |
| HK1092132A (en) | Propionic acid derivatives useful in the treatment of lipid disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20080915 |